Oct 23 (Reuters) - Fuso Pharmaceutical Industries Ltd <4538.T>:Says it will sell Aichi-based property on Oct. 31, and capital gains is 567 million yen .
Sept 5(Reuters) - Fuso Pharmaceutical Industries Ltd <4538.T>:Says it completes repurchase of 154,100 shares of its common stock.Shares repurchased at the price of 2,736 yen per share, or 421.6 million yen in total, on Sept. 5, through ToSTNeT-3.
Sept 4 (Reuters) - Fuso Pharmaceutical Industries Ltd <4538.T>:Says it plans to repurchase up to 200,000 shares of its common stock on Sept. 5.Share repurchase price is 2,736 yen per share, the closing price of Sept. 4, or up to 547.2 million yen in total.
Fuso Pharmaceutical Industries Ltd <4538.T>: Says it plans to sell Fukuoka-based parking lot on Nov. 29 .Says the selling price is not disclosed.
Fuso Pharmaceutical Industries Ltd:Says recall of two kinds of transfusion related products.The recall due to content filling error.
Fuso Pharmaceutical Industries Ltd:Says the company increased the mid-year outlook for revenue to 23,200 mln yen from 23,000 mln yen, for the fiscal year ending March 31, 2016.Sees a decrease of operating profit forecast to 180 mln yen from 300 mln yen.Sees a decrease of ordinary profit forecast to 180 mln yen from 200 mln yen.Sees a decrease of net profit forecast to 100 mln yen from 140 mln yen.Sees a decrease of earnings per share to 1.11 yen from 1.55 yen.Says profit outlook lowered due to the increased cost.
Otsuka Holdings Co Ltd:Otsuka Pharmaceutical Co., Ltd. (Otsuka), a wholly-owned subsidiary of Otsuka Holdings Co. Ltd., announces as follows.That the exclusive licensing contract that has been in effect with OncoTherapy Science, Inc. (OTS) for the development, manufacture, and marketing of a peptide therapeutic vaccine for the treatment of pancreatic cancer, will be allowed to expire.The contract will be allowed to expire, following 180-day prior notification, at the scheduled end date of the contract period.A sublicensing contract which has been in effect with Fuso Pharmaceutical Industries, Ltd. for the manufacture and marketing in Japan of OTS102, a therapeutic vaccine, will also be allowed to expire on the same date.Otsuka will continue its efforts in oncology as a priority area. This will include the development of the peptide therapeutic vaccine OCV-C02, for which a phase 1 clinical study is currently underway in colon cancer based on a contract with OTS.
3-D Matrix Ltd, KAKEN PHARMACEUTICAL CO LTD and Fuso Pharmaceutical Industries Ltd:Cancels quasi-exclusive distribution agreement on TDM-621, which is developed by 3-D Matrix as hemostatic agent, on Dec. 22.
Fuso Pharmaceutical Industries Ltd:Says the company lowered the consolidated full-year outlook for the FY ending March 2015.Revenue forecast decreased to 47,600 million yen from 48,800 million yen.Operating profit forecast decreased to 600 million yen from 1,500 million yen.Ordinary profit forecast decreased to 500 million yen from 1,400 million yen.Net profit forecast decreased to 350 million yen from 900 million yen.Earnings per share decreased to 3.87 yen from 9.94 yen.Comments that deterioration of the market environment and increased cost of sales ratio are the main reasons for the forecast.
Fuso Pharmaceutical Industries Ltd:Says the company lowered the consolidated mid-year outlook for revenue to 23,400 million yen from 24,400 million yen for FY ending March 2015.Sees a decrease of operating profit forecast to 340 million yen from 800 million yen.Sees a decrease of ordinary profit forecast to 320 million yen from 750 million yen.Sees a decrease of net profit forecast to 200 million yen from 500 million yen.Sees a decrease of earnings per share to 2.21 yen from 5.52 yen.Comments the sales decrease and increased cost of sales ratio are the main reasons for the forecast.